SCHEMBL20154516

SCHEMBL20154516

Cc1ccc(S(=O)(=O)N2CC23CCN(C)CC3)cc1

nearest known ligand 0.57

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.50
PKM P14618 3/20 0.47
ALDH1A1 P00352 1/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.46
TSHR P16473 2/20 0.44
MEN1 O00255 2/20 0.43
GAA P10253 1/20 0.43
CYP2C19 P33261 1/20 0.43
MMP2 P08253 1/20 0.42
HTR2A P28223 1/20 0.42
HTR2C P28335 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20071375 0.86 KMT2A (0.49) KMT2APKMALDH1A1POLBHTT
SCHEMBL22812232 0.86 TSHR (0.60) KMT2AALDH1A1POLBTSHRMEN1
SCHEMBL12296593 0.85 KMT2A (0.54) KMT2APKMALDH1A1POLBHTT
SCHEMBL1919732 0.84 KMT2A (0.53) KMT2APKMALDH1A1POLBHTT
SCHEMBL20153278 0.84 NPC1 (0.54) PKMALDH1A1HTTTSHRGAA
SCHEMBL20626519 0.84 KDM2B (0.51) KMT2APKMALDH1A1POLBHTT
SCHEMBL20148747 0.84 GAA (0.60) KMT2APKMALDH1A1POLBHTT
SCHEMBL20160470 0.81 GAA (0.47) KMT2APKMALDH1A1POLBHTT
SCHEMBL1920025 0.81 KMT2A (0.50) KMT2APKMALDH1A1POLBHTT
SCHEMBL2438590 0.81 KMT2A (0.50) KMT2APKMALDH1A1POLBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors ELI LILLY AND COMPANY (US) 2020-02-11 US disclosed
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2019-06-20 US disclosed
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS ARRAY BIOPHARMA INC. 2018-05-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10555944-B2 Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors RET, ROR1, BRAF KMT2A 1171/4885PKM 1138/4885ALDH1A1 2868/4885
US-20190183886-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF KMT2A 1171/4885PKM 1138/4885ALDH1A1 2868/4885
US-20180133213-A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS RET, ROR1, BRAF KMT2A 1171/4885PKM 1138/4885ALDH1A1 2868/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.